Data / Drug companies / Celgene Corporation
Celgene Corporation: 30 products in the FDA NDC directory, labeler code 59572
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Celgene Corporation (labeler code 59572) lists 30 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 26 prescription drugs, 3 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on March 26, 2021.
The request: Watch Celgene Corporation (FDA labeler code 59572): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 59572
- Products in commercial distribution
- 30
- Packages
- 45
- Finished drugs by generic name
- 10
- Prescription products
- 26
- Over the counter products
- 0
- Flagged as original packager
- 22 of 22 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- June 20, 2003
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 24 | 80% |
| Biologics (BLA) | 3 | 10% |
| Drugs for further processing | 3 | 10% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 26 | 86.7% |
| Drugs for further processing | 3 | 10% |
| Cellular therapies | 1 | 3.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Lenalidomide | 6 | 19 |
| Pomalidomide | 4 | 12 |
| Thalidomide | 4 | 1 |
| Azacitidine | 3 | 20 |
| Ozanimod hydrochloride | 3 | 1 |
| Enasidenib mesylate | 2 | 1 |
| Luspatercept | 2 | 1 |
| Idecabtagene vicleucel | 1 | 1 |
| Romidepsin | 1 | 5 |
| Fedratinib hydrochloride | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 19 | 63.3% |
| Tablet, film coated | 4 | 13.3% |
| Kit | 3 | 10% |
| Injection, powder, lyophilized, for solution | 3 | 10% |
| Suspension | 1 | 3.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Thalidomide Analog | 10 |
| Nucleoside Metabolic Inhibitor | 3 |
| Isocitrate Dehydrogenase 2 Inhibitor | 2 |
| Erythroid Maturation Agent | 2 |
| Sphingosine 1-phosphate Receptor Modulator | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Abecma | 59572-515 | Suspension | Biologics (BLA) | March 26, 2021 |
| Onureg | 59572-740 | Tablet, film coated | New drug applications (NDA) | September 1, 2020 |
| Onureg | 59572-730 | Tablet, film coated | New drug applications (NDA) | September 1, 2020 |
| ZEPOSIA Starter Kit | 59572-890 | Kit | New drug applications (NDA) | March 27, 2020 |
| Zeposia | 59572-820 | Capsule | New drug applications (NDA) | March 27, 2020 |
| Ozanimod hydrochloride | 59572-816 | Capsule | Drugs for further processing | March 27, 2020 |
| Ozanimod hydrochloride | 59572-814 | Capsule | Drugs for further processing | March 27, 2020 |
| Ozanimod hydrochloride | 59572-812 | Capsule | Drugs for further processing | March 27, 2020 |
| ZEPOSIA 7-Day Starter Pack | 59572-810 | Kit | New drug applications (NDA) | March 27, 2020 |
| Reblozyl | 59572-775 | Injection, powder, lyophilized, for solution | Biologics (BLA) | November 8, 2019 |
| Reblozyl | 59572-711 | Injection, powder, lyophilized, for solution | Biologics (BLA) | November 8, 2019 |
| Inrebic | 59572-720 | Capsule | New drug applications (NDA) | August 16, 2019 |
| Idhifa | 59572-710 | Tablet, film coated | New drug applications (NDA) | August 1, 2017 |
| Idhifa | 59572-705 | Tablet, film coated | New drug applications (NDA) | August 1, 2017 |
| Revlimid | 59572-420 | Capsule | New drug applications (NDA) | June 6, 2013 |
| Pomalyst | 59572-504 | Capsule | New drug applications (NDA) | February 18, 2013 |
| Pomalyst | 59572-503 | Capsule | New drug applications (NDA) | February 18, 2013 |
| Pomalyst | 59572-502 | Capsule | New drug applications (NDA) | February 18, 2013 |
| Pomalyst | 59572-501 | Capsule | New drug applications (NDA) | February 18, 2013 |
| Revlimid | 59572-402 | Capsule | New drug applications (NDA) | April 16, 2012 |
| Istodax | 59572-984 | Kit | New drug applications (NDA) | January 4, 2010 |
| Thalomid | 59572-215 | Capsule | New drug applications (NDA) | March 20, 2007 |
| Revlimid | 59572-425 | Capsule | New drug applications (NDA) | June 29, 2006 |
| Revlimid | 59572-415 | Capsule | New drug applications (NDA) | June 29, 2006 |
| Revlimid | 59572-410 | Capsule | New drug applications (NDA) | December 27, 2005 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.